Gilead Sciences Inc. (GILD)
Gilead (GILD) Loses 17.6% YTD: How Should You Play the Stock?
While Gilead (GILD) has been reeling under pressure year to date due to pipeline setbacks, holding on to this biotech giant will be prudent at current levels.
Analyst: Science Stock Sports Long-Term Support
Shares of drugmaker Gilead Sciences, Inc. (NASDAQ:GILD) are up 2% in pre-market trading, after Raymond James upgraded the stock to "outperform" from "market perform.
Gilead Records Positive Phase III Results In HIV
Gilead Sciences reports positive Phase III trial results for lenacapavir, showing zero incident cases of HIV infection in the treatment group. Results suggest the potential for lenacapavir to revolutionize HIV prevention and treatment, leading to market expansion and creating shareholder value. Gilead's diversified revenue streams from HIV, liver disease, COVID-19, and oncology products position the company for continued growth and success.
GILD Stock Today: Why A Broken Wing Butterfly Might Make Money In Gilead Sciences Stock
Support for Gilead shares sits near 57.
Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection
Gilead's (GILD) twice-yearly, subcutaneous lenacapavir has demonstrated its potential as a new tool to help prevent HIV infections with zero infections and 100% efficacy. Shares gain.
Gilead Sciences Stock Surges on HIV Treatment Trial Success
Gilead Sciences NASDAQ: GILD saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. The biopharmaceutical company revealed 100% efficacy in its Phase 3 HIV prevention trial, marking the first trial showing zero infections.
Strength Seen in Gilead (GILD): Can Its 8.5% Jump Turn into More Strength?
Gilead (GILD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Gilead Stock Surges on Strong Results in HIV Drug Study
Gilead Sciences (GILD) surged over 8% in intraday trading Thursday as the biotech firm announced a Phase 3 trial found its injectable lenacapavir was 100% effective in preventing HIV infection in women.
Gilead surges as HIV prevention therapy shows 100% efficacy in late-stage trial
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) shares added more than 8% after the pharmaceutical firm unveiled new data from a late-stage PURPOSE trial which showed its twice-yearly injectable HIV therapy lenacapavir is 100% effective in preventing HIV in women. Notably, lenacapavir was shown to be superior to once-daily oral Truvada, which is one of several medications currently used to treat HIV and to prevent HIV infection, known as pre-exposure prophylaxis (PrEP).
2 Pharma Stocks Moving in Different Directions Today
Stocks are all over the place today, with the Dow confidently higher, the Nasdaq choppy, and the S&P 500 contending with a psychologically-significant level.
Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective
Gilead stock surged Thursday after its twice-annual shot proved 100% effective in preventing HIV infections in cisgender women.
Gilead's twice-yearly shot to prevent HIV succeeds in late-stage trial
Gilead's twice-yearly medicine to prevent HIV succeeded in a Phase 3 trial. None of the roughly 2,000 women in the trial who received the shot, lenacapavir, contracted HIV.
